English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Lung cancer is a major cause of mortality worldwide and non-small cell lung cancer (NSCLC) accounts for over 80% of all cases of lung cancer. Despite efforts to develop and improve early screening methods, the majority of tumors are detected at advanced stages. For over 30 years, cisplatin (CDDP), or any of its analogues, has been used in the treatment of many types of tumors, including lung cancer. The use of platinum-based chemotherapeutics is limited by their toxicity and later on by the development of chemoresistance by tumor cells. The molecular mechanisms of CDDP resistance are not fully resolved. Genetic variants of DNA repair proteins, as well as proteins involved in drug accumulation or detoxification, play a crucial role in determining the cell's response to platinum-based chemotherapy. The identification of selected gene polymorphisms could improve the prognosis of a patient's response to therapy and overall survival. In this review we will focus on the gene polymorphisms involved in CDDP resistance, in particular in lung tumors, and discuss their potential as prognosis and survival markers.

Single nucleotide polymorphisms in lung cancer patients and cisplatin treatment